Medium_EnglishPassage_2034
Growth of the Pharmaceutical Industry

Words: 415, Characters: 3066 **LEVEL: MEDIUM**

The Indian pharmaceutical sector, globally recognized as the 'Pharmacy of the World', is currently the third-largest producer of medicines by volume and ranks fourteenth in terms of overall market value. Boasting an extensive network of over 3,000 drug companies and approximately 10,500 manufacturing units, the industry plays a highly critical role in maintaining global public health. The foundational strength of this sector lies in its unmatched ability to manufacture high-quality, life-saving generic medicines at a fraction of the cost charged by Western multinational corporations (MNCs). For example, in the early 2000s, an annual course of anti-retroviral therapy (ART) for HIV/AIDS patients cost around 10,000 in the United States; Indian manufacturers completely disrupted this monopoly by offering the exact same treatment for less than 400/year. This aggressive pricing strategy allowed millions of impoverished patients in African and Asian countries to access affordable healthcare. During the 2020-2021 global health emergency, the industry demonstrated exceptional resilience: it exported over 65 million doses of locally manufactured vaccines to 95 different countries under the 'Vaccine Maitri' diplomatic initiative. Currently, the national pharmaceutical export market is valued at approximately 25.3 billion, with a highly ambitious target of crossing the 50 billion mark by the year 2030. Despite this phenomenal global success, the industry relies dangerously on foreign imports for its raw materials. Nearly 70% of all Active Pharmaceutical Ingredients (APIs)—the core chemical compounds required to make a tablet or syrup—are currently imported from a single neighboring country. Any sudden disruption in this cross-border supply chain can instantly paralyze domestic drug production. To mitigate this severe strategic vulnerability, the central government has allocated 6,940 crores for a Production Linked Incentive (PLI) scheme; this initiative provides massive tax rebates to companies that establish bulk-drug manufacturing parks within the country. Furthermore, if domestic companies wish to evolve from simple 'copy-cat' manufacturers into global medical leaders, they must heavily increase their annual budgets for Research and Development (R&D). Discovering a brand-new, patented molecule requires highly sophisticated laboratories, strict clinical trials, and investments running into billions of dollars over a 10-15 year period. Additionally, maintaining impeccable quality-control standards is non-negotiable; recent incidents involving contaminated cough syrups exported to African nations have severely tarnished the country's reliable reputation. The national regulatory authority—the Central Drugs Standard Control Organisation

© 2026 TypingGuru App Download From Playstore

(CDSCO)—must strictly penalize any manufacturing unit failing to meet international safety protocols. By bridging the gap between academic biological research and commercial drug production, the pharmaceutical sector can ensure a healthy, self-reliant future for both the nation and the world.

2856
2935
3011
3066